Ironwood Pharmaceuticals, Inc. - (IRWD): Price and Financial Metrics
Today's Latest Price: $10.39 USD
Jan 27 4:00pm Add IRWD to Watchlist Sign Up
IRWD Stock Summary Ironwood Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 99.57% of US listed stocks. IRWD's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 2.03% of US stocks. Over the past twelve months, IRWD has reported earnings growth of -5,180.87%, putting it ahead of merely 0.52% of US stocks in our set. If you're looking for stocks that are quantitatively similar to Ironwood Pharmaceuticals Inc, a group of peers worth examining would be CLPT, FKWL, CAMP, FLGT, and DAIO. IRWD's SEC filings can be seen here. And to visit Ironwood Pharmaceuticals Inc's official web site, go to www.ironwoodpharma.com.
IRWD Price/Volume Stats
Ironwood Pharmaceuticals, Inc. - (IRWD) Company Bio
Ironwood Pharmaceuticals engages in the research, development, and commercialization of human therapeutic products, with a key focus being the treatment of adult men and women suffering from irritable bowel syndrome. The company was founded in 1998 and is based in Cambridge, Massachusetts.
IRWD Latest News Stream
All News Types
Loading, please wait...
Latest IRWD News From Around the Web
Below are the latest news stories about Ironwood Pharmaceuticals Inc that investors may wish to consider to help them evaluate IRWD as an investment opportunity.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, will provide a corporate overview during a presentation and Q&A se
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
JAZZ announces the failure of a combination regimen of SCLC drug, Zepzelca, to meet primary endpoint in a late-stage study. However, overall study data seems promising for the drug. Stock up.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately. Mr. Shepard will also serve as a member of the Audit Committee. Following the appointment of Mr. Shepard, the Board is now composed of 11 directors, nine of whom are independent.
FibroGen's (FGEN) Evrenzo (roxadustat) wins second approval in Japan for treating anemia caused by chronic kidney disease in non-dialysis-dependent patients.
Read More 'IRWD' Stories Here
IRWD Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.7458 seconds.